FR2862648B1 - Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c - Google Patents

Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c

Info

Publication number
FR2862648B1
FR2862648B1 FR0313649A FR0313649A FR2862648B1 FR 2862648 B1 FR2862648 B1 FR 2862648B1 FR 0313649 A FR0313649 A FR 0313649A FR 0313649 A FR0313649 A FR 0313649A FR 2862648 B1 FR2862648 B1 FR 2862648B1
Authority
FR
France
Prior art keywords
novel
virus
preparation
pharmaceutical compositions
active against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0313649A
Other languages
English (en)
Other versions
FR2862648A1 (fr
Inventor
Anne Fournillier
Genevieve Inchauspe
Perrine Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA filed Critical Biomerieux SA
Priority to FR0313649A priority Critical patent/FR2862648B1/fr
Priority to PCT/FR2004/050581 priority patent/WO2005051420A1/fr
Publication of FR2862648A1 publication Critical patent/FR2862648A1/fr
Application granted granted Critical
Publication of FR2862648B1 publication Critical patent/FR2862648B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR0313649A 2003-11-21 2003-11-21 Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c Expired - Fee Related FR2862648B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0313649A FR2862648B1 (fr) 2003-11-21 2003-11-21 Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
PCT/FR2004/050581 WO2005051420A1 (fr) 2003-11-21 2004-11-10 Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313649A FR2862648B1 (fr) 2003-11-21 2003-11-21 Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c

Publications (2)

Publication Number Publication Date
FR2862648A1 FR2862648A1 (fr) 2005-05-27
FR2862648B1 true FR2862648B1 (fr) 2006-02-03

Family

ID=34531167

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0313649A Expired - Fee Related FR2862648B1 (fr) 2003-11-21 2003-11-21 Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c

Country Status (2)

Country Link
FR (1) FR2862648B1 (fr)
WO (1) WO2005051420A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149389A1 (fr) * 2010-05-27 2011-12-01 Gutkina, Anna Ilinichna Composition immunogène pour le traitement de l'hépatite c, son procédé de fabrication et son utilisation dans le traitement de l'hépatite c

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
EP1748067A1 (fr) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides codant pour des épitopes de la hTERT restreints au CMH de classe I, analogues et polyépitopes
KR20110116016A (ko) 2009-01-20 2011-10-24 트랜스진 에스.에이. 치료적 반응의 예측을 위한 바이오마커로서의 가용성 ｉｃａｍ―１
US20120028279A1 (en) 2009-03-24 2012-02-02 Bruce Acres Biomarker for monitoring patients
PT2419728E (pt) 2009-04-17 2014-03-12 Transgene Sa Marcadores biológicos para monitorizar doentes
RU2514034C2 (ru) * 2012-08-14 2014-04-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Способ вакцинотерапии герпетической инфекции

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
FR2839722A1 (fr) * 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149389A1 (fr) * 2010-05-27 2011-12-01 Gutkina, Anna Ilinichna Composition immunogène pour le traitement de l'hépatite c, son procédé de fabrication et son utilisation dans le traitement de l'hépatite c
RU2447899C2 (ru) * 2010-05-27 2012-04-20 Михаил Валентинович Филатов Композиция для лечения гепатита с и способ лечения гепатита с

Also Published As

Publication number Publication date
WO2005051420A1 (fr) 2005-06-09
FR2862648A1 (fr) 2005-05-27

Similar Documents

Publication Publication Date Title
WO2007047146A3 (fr) Inhibiteurs de réplication virale
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
IL164845A (en) 2-(alpha-hydroxypentyl)benzoate, its preparation, pharmaceutical compositions comprising it and their use in the preparation of medicaments
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
EE200200151A (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
AR077411A2 (es) Forma de dosificacion farmaceutica solida, con lopinavir y ritonavir, y proceso para su preparacion.
AU2001268373A1 (en) Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
FR2825705B1 (fr) Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
WO2004080428A3 (fr) Applications therapeutiques, nutraceutiques et cosmetiques pour preparations a base de membranes de coquilles d'oeufs et de membranes de coquilles d'oeufs traitees
FR2835528B1 (fr) Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
FR2884252B1 (fr) Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AU2003270255A1 (en) Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve
DE60142340D1 (de) Mischungen von polysacchariden aus heparin, deren herstellung und diese enthaltende pharmazeutische zubereitungen
EE200400028A (et) Ravimpreparaat, selle valmistamise meetod ja selle kasutamine meditsiinis
FR2862648B1 (fr) Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
NO20055601D0 (no) Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
WO2005079750A3 (fr) Pellicules pour formes posologiques
SI1890692T1 (sl) Formulacije lipojske kisline in benzil estra hialuronske kisline na farmacevtskih in kozmetiäśnih podroäśjih
IT1319210B1 (it) Pellicola per la somministrazione dermica e transdermica di principiattivi.
NO20001905D0 (no) Forbindelser og deres anvendelse i farmasøytiske eller kosmetiske preparater

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100730